On Monday, Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) opened higher 3.33% from the last session, before settling in for the closing price of $1.80. Price fluctuations for LXRX have ranged from $0.92 to $3.73 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 186.21% over the last five years. Company’s average yearly earnings per share was noted 14.05% at the time writing. With a float of $349.07 million, this company’s outstanding shares have now reached $361.49 million.
The firm has a total of 285 workers. Let’s measure their productivity. In terms of profitability, gross margin is 80.66%, operating margin of -5412.11%, and the pretax margin is -5509.34%.
Lexicon Pharmaceuticals Inc (LXRX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lexicon Pharmaceuticals Inc is 3.44%, while institutional ownership is 76.94%. The most recent insider transaction that took place on Aug 15 ’24, was worth 480,000. Before that another transaction happened on Nov 16 ’23, when Company’s Chief Executive Officer bought 90,000 for $1.05, making the entire transaction worth $94,797. This insider now owns 914,359 shares in total.
Lexicon Pharmaceuticals Inc (LXRX) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.21 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.21) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.05% per share during the next fiscal year.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Trading Performance Indicators
Check out the current performance indicators for Lexicon Pharmaceuticals Inc (LXRX). In the past quarter, the stock posted a quick ratio of 11.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 184.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.77, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.59 in one year’s time.
Technical Analysis of Lexicon Pharmaceuticals Inc (LXRX)
Analysing the last 5-days average volume posted by the [Lexicon Pharmaceuticals Inc, LXRX], we can find that recorded value of 2.88 million was lower than the volume posted last year of 3.37 million. As of the previous 9 days, the stock’s Stochastic %D was 20.51%. Additionally, its Average True Range was 0.12.
During the past 100 days, Lexicon Pharmaceuticals Inc’s (LXRX) raw stochastic average was set at 38.54%, which indicates a significant decrease from 45.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.93% in the past 14 days, which was lower than the 76.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7180, while its 200-day Moving Average is $1.9085. Now, the first resistance to watch is $1.9350. This is followed by the second major resistance level at $2.0100. The third major resistance level sits at $2.0750. If the price goes on to break the first support level at $1.7950, it is likely to go to the next support level at $1.7300. Now, if the price goes above the second support level, the third support stands at $1.6550.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Key Stats
There are currently 246,237K shares outstanding in the company with a market cap of 672.37 million. Presently, the company’s annual sales total 1,200 K according to its annual income of -177,120 K. Last quarter, the company’s sales amounted to 1,650 K and its income totaled -53,430 K.
